Global throat cancer diagnostics market is projected to register a substantial CAGR of 7.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation:
Global Throat Cancer Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, and Others), Cancer Type (Pharyngeal Cancer and Laryngeal Cancer), Stages (Stage 0, Stage I, Stage II, Stage III and Stage IV), Age Group (30-65, 65 and above, 21-29 and Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes and Others) and By Distribution Channel (Direct Tender and Retail Sales), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Belgium, Switzerland, Rest of Europe, China, Japan, South Korea, India, Thailand, Singapore, Indonesia, Malaysia, Philippines, Australia, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and Rest of Middle East and Africa), Industry Trends and Forecast to 2030.
Growing prevalence of throat cancer
Novel technological advancements in throat cancer diagnostics
Market Players:
Some of the key market players in global throat cancer diagnostics market are listed below:
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
QIAGEN
Abbott
Siemens Healthcare GmbH
Merck KGAA
Hologic, Inc.
Agilent Technologies, Inc.
Illumina, Inc.
BIOMERIEUX
Myriad Genetics, Inc.
Quest Diagnostics Incorporated.
Bio-Rad Laboratories, Inc.
Koninklijke Philips N.V.
BD
Time Medical Holding
PlexBio
MinFound Medical Systems Co., Ltd
Medonica Co. LTD
CANON MEDICAL SYSTEMS CORPORATION
Sysmex Corporation
SternMed GmbH
FUJIFILM Corporation
TABLE OF CONTENTS
1 INTRODUCTION 47
- 1.1 OBJECTIVES OF THE STUDY 47
- 1.2 MARKET DEFINITION 47
- 1.3 OVERVIEW OF THE GLOBAL THROAT CANCER DIAGNOSTICS MARKET 47
- 1.4 LIMITATIONS 49
- 1.5 MARKETS COVERED 49
2 MARKET SEGMENTATION 52
- 2.1 MARKETS COVERED 52
- 2.2 GEOGRAPHICAL SCOPE 53
- 2.3 YEARS CONSIDERED FOR THE STUDY 54
- 2.4 CURRENCY AND PRICING 54
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
- 2.6 MULTIVARIATE MODELLING 58
- 2.7 PRODUCT TYPE LIFELINE CURVE 58
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
- 2.9 DBMR MARKET POSITION GRID 60
- 2.10 MARKET END USER COVERAGE GRID 61
- 2.11 VENDOR SHARE ANALYSIS 62
- 2.12 SECONDARY SOURCES 63
- 2.13 ASSUMPTIONS 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 67
- 4.1 PESTEL ANALYSIS 70
- 4.2 PORTER'S FIVE FORCES 71
5 INDUSTRY INSIGHTS 72
6 EPIDEMIOLOGY 73
7 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, REGULATIONS 74
- 7.1 REGULATORY SCENARIO IN THE U.S 74
- 7.2 REGULATORY SCENARIO IN AUSTRALIA 75
- 7.3 REGULATORY SCENARIO IN JAPAN 75
- 7.4 REGULATORY SCENARIO IN CHINA 75
8 MARKET OVERVIEW 77
- 8.1 DRIVERS 79
- 8.1.1 GROWING PREVALENCE OF THROAT CANCER 79
- 8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN THROAT CANCER DIAGNOSTICS 79
- 8.1.3 INCREASE IN AWARENESS REGARDING THROAT CANCER 80
- 8.2 RESTRAINTS 80
- 8.2.1 LATE DIAGNOSIS AND POOR PROGNOSIS OF THROAT CANCER 80
- 8.2.2 HIGH COST FOR THE INSTALLATION OF DIAGNOSTIC DEVICES. 80
- 8.3 OPPORTUNITIES 81
- 8.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 81
- 8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 82
- 8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 82
- 8.4 CHALLENGES 83
- 8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 83
- 8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 83
9 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 84
- 9.1 OVERVIEW 85
- 9.2 INSTRUMENTS 88
- 9.2.1 PATHOLOGY-BASED INSTRUMENTS 89
- 9.2.1.1 PCR INSTRUMENTS 89
- 9.2.1.2 SLIDE STAINING SYSTEMS 89
- 9.2.1.3 TISSUE PROCESSING SYSTEMS 90
- 9.2.1.4 CELL PROCESSORS 90
- 9.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 90
- 9.2.2 IMAGING INSTRUMENTS 90
- 9.2.2.1 ULTRASOUND SYSTEMS 90
- 9.2.2.2 CT SYSTEMS 90
- 9.2.2.3 MRI SYSTEMS 90
- 9.2.2.4 OTHERS 91
- 9.2.3 BIOPSY INSTRUMENTS 91
- 9.2.4 OTHERS 91
- 9.3 CONSUMABLES & ACCESSORIES 91
- 9.3.1 KITS 92
- 9.3.1.1 PCR KITS 92
- 9.3.1.2 DNA POLYMERASE KITS 92
- 9.3.1.3 NUCLEIC ACID ISOLATION KITS 92
- 9.3.1.4 OTHERS 93
- 9.3.2 REAGENTS 93
- 9.3.2.1 ASSAYS 93
- 9.3.2.2 BUFFERS 93
- 9.3.2.3 PRIMERS 93
- 9.3.2.4 OTHERS 93
- 9.3.3 PROBES 93
- 9.3.4 OTHER CONSUMABLES 93
10 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY TEST TYPE 94
- 10.1 OVERVIEW 95
- 10.2 IMAGING TEST 98
- 10.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 99
- 10.2.2 MRI 99
- 10.2.3 CHEST X-RAY 99
- 10.2.4 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 99
- 10.2.5 OTHERS 99
- 10.3 BLOOD TEST 99
- 10.3.1 BLOOD CHEMISTRY TESTS 101
- 10.3.2 COMPLETE BLOOD COUNT (CBC) 101
- 10.3.3 OTHERS 101
- 10.4 BIOPSY 101
- 10.4.1 ENDOSCOPIC BIOPSY 102
- 10.4.2 FINE NEEDLE ASPIRATION (FNA) BIOPSY 102
- 10.4.3 OTHERS 102
- 10.5 OTHERS 103
11 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 104
- 11.1 OVERVIEW 105
- 11.2 PHARYNGEAL CANCER 108
- 11.2.1 NASOPHARYNGEAL CANCER 109
- 11.2.2 OROPHARYNGEAL CANCER 109
- 11.2.3 HYPOPHARYNGEAL CANCER 109
- 11.3 LARYNGEAL CANCER 110
12 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY STAGES 111
- 12.1 OVERVIEW 112
- 12.2 STAGE III 115
- 12.3 STAGE II 115
- 12.4 STAGE IV 116
- 12.5 STAGE I 117
- 12.6 STAGE 0 118
13 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY AGE 119
- 13.1 OVERVIEW 120
- 13.2 30-65 123
- 13.3 65 AND ABOVE 124
- 13.4 21-29 124
- 13.5 BELOW 21 125
14 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY END USER 126
- 14.1 OVERVIEW 127
- 14.2 HOSPITALS 130
- 14.3 ASSOCIATED LABS 130
- 14.4 INDEPENDENT DIAGNOSTIC LABORATORIES 131
- 14.5 DIAGNOSTIC IMAGING CENTERS 132
- 14.6 CANCER RESEARCH INSTITUTES 133
- 14.7 OTHERS 134
15 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 135
- 15.1 OVERVIEW 136
- 15.2 DIRECT TENDER 139
- 15.3 RETAIL SALES 140
16 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY REGION 141
- 16.1 OVERVIEW 142
- 16.2 NORTH AMERICA 148
- 16.2.1 U.S. 158
- 16.2.2 CANADA 163
- 16.2.3 MEXICO 168
- 16.3 EUROPE 173
- 16.3.1 GERMANY 183
- 16.3.2 FRANCE 188
- 16.3.3 U.K. 193
- 16.3.4 ITALY 198
- 16.3.5 SPAIN 203
- 16.3.6 RUSSIA 208
- 16.3.7 TURKEY 213
- 16.3.8 NETHERLANDS 218
- 16.3.9 BELGIUM 223
- 16.3.10 SWITZERLAND 228
- 16.3.11 REST OF EUROPE 233
- 16.4 ASIA-PACIFIC 234
- 16.4.1 CHINA 245
- 16.4.2 JAPAN 250
- 16.4.3 SOUTH KOREA 255
- 16.4.4 INDIA 260
- 16.4.5 THAILAND 265
- 16.4.6 SINGAPORE 270
- 16.4.7 INDONESIA 275
- 16.4.8 MALAYSIA 280
- 16.4.9 PHILIPPINES 285
- 16.4.10 AUSTRALIA 290
- 16.4.11 VIETNAM 295
- 16.4.12 REST OF ASIA-PACIFIC 300
- 16.5 SOUTH AMERICA 301
- 16.5.1 BRAZIL 310
- 16.5.2 ARGENTINA 315
- 16.5.3 REST OF SOUTH AMERICA 320
- 16.6 MIDDLE EAST AND AFRICA 321
- 16.6.1 SAUDI ARABIA 332
- 16.6.2 U.A.E 337
- 16.6.3 SOUTH AFRICA 342
- 16.6.4 EGYPT 347
- 16.6.5 ISRAEL 352
- 16.6.6 REST OF MIDDLE EAST AND AFRICA 357
17 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 358
- 17.1 COMPANY SHARE ANALYSIS: GLOBAL 358
- 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 359
- 17.3 COMPANY SHARE ANALYSIS: EUROPE 360
- 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 361
18 SWOT ANALYSIS 362
19 COMPANY PROFILE 363
- 19.1 F. HOFFMANN- LA ROCHE LTD 363
- 19.1.1 COMPANY SNAPSHOT 363
- 19.1.2 REVENUE ANALYSIS 363
- 19.1.3 COMPANY SHARE ANALYSIS 364
- 19.1.4 PRODUCT PORTFOLIO 364
- 19.1.5 RECENT DEVELOPMENT 364
- 19.2 FUJIFILM CORPORATION 365
- 19.2.1 COMPANY SNAPSHOT 365
- 19.2.2 REVENUE ANALYSIS 365
- 19.2.3 COMPANY SHARE ANALYSIS 366
- 19.2.4 PRODUCT PORTFOLIO 366
- 19.2.5 RECENT DEVELOPMENT 366
- 19.3 THERMO FISHER SCIENTIFIC INC. 367
- 19.3.1 COMPANY SNAPSHOT 367
- 19.3.2 REVENUE ANALYSIS 367
- 19.3.3 COMPANY SHARE ANALYSIS 368
- 19.3.4 PRODUCT PORTFOLIO 368
- 19.3.5 RECENT DEVELOPMENTS 368
- 19.4 CANON MEDICAL SYSTEMS CORPORATION 369
- 19.4.1 COMPANY SNAPSHOT 369
- 19.4.2 REVENUE ANALYSIS 369
- 19.4.3 COMPANY SHARE ANALYSIS 370
- 19.4.4 PRODUCT PORTFOLIO 370
- 19.4.5 RECENT DEVELOPMENT 370
- 19.5 KONINKLIJKE PHILIPS N.V. 371
- 19.5.1 COMPANY SNAPSHOT 371
- 19.5.2 REVENUE ANALYSIS 371
- 19.5.3 COMPANY SHARE ANALYSIS 372
- 19.5.4 PRODUCT PORTFOLIO 372
- 19.5.5 RECENT DEVELOPMENT 373
- 19.6 ABBOTT 374
- 19.6.1 COMPANY SNAPSHOT 374
- 19.6.2 REVENUE ANALYSIS 374
- 19.6.3 PRODUCT PORTFOLIO 375
- 19.6.4 RECENT DEVELOPMENTS 375
- 19.7 AGILENT TECHNOLOGIES, INC. 376
- 19.7.1 COMPANY SNAPSHOT 376
- 19.7.2 REVENUE ANALYSIS 376
- 19.7.3 PRODUCT PORTFOLIO 377
- 19.7.4 RECENT DEVELOPMENT 377
- 19.8 BD 378
- 19.8.1 COMPANY SNAPSHOT 378
- 19.8.2 REVENUE ANALYSIS 378
- 19.8.3 PRODUCT PORTFOLIO 379
- 19.8.4 RECENT DEVELOPMENTS 379
- 19.9 BEIJING O&D BIOTECH CO., LTD. 380
- 19.9.1 COMPANY SNAPSHOT 380
- 19.9.2 PRODUCT PORTFOLIO 380
- 19.9.3 RECENT DEVELOPMENT 380
- 19.10 BIO-RAD LABORATORIES, INC. 381
- 19.10.1 COMPANY SNAPSHOT 381
- 19.10.2 REVENUE ANALYSIS 381
- 19.10.3 PRODUCT PORTFOLIO 382
- 19.10.4 RECENT DEVELOPMENT 382
- 19.11 FONAR CORP. 383
- 19.11.1 COMPANY SNAPSHOT 383
- 19.11.2 REVENUE ANALYSIS 383
- 19.11.3 PRODUCT PORTFOLIO 384
- 19.11.4 RECENT DEVELOPMENT 384
- 19.12 GE HEALTHCARE 385
- 19.12.1 COMPANY SNAPSHOT 385
- 19.12.2 REVENUE ANALYSIS 385
- 19.12.3 PRODUCT PORTFOLIO 386
- 19.12.4 RECENT DEVELOPMENT 386
- 19.13 HOLOGIC INC. 387
- 19.13.1 COMPANY SNAPSHOT 387
- 19.13.2 REVENUE ANALYSIS 387
- 19.13.3 PRODUCT PORTFOLIO 388
- 19.13.4 RECENT DEVELOPMENT 388
- 19.14 ILLUMINA, INC. 389
- 19.14.1 COMPANY SNAPSHOT 389
- 19.14.2 REVENUE ANALYSIS 389
- 19.14.3 PRODUCT PORTFOLIO 390
- 19.14.4 RECENT DEVELOPMENT 390
- 19.15 MEDONICA CO. LTD 391
- 19.15.1 COMPANY SNAPSHOT 391
- 19.15.2 PRODUCT PORTFOLIO 391
- 19.15.3 RECENT DEVELOPMENT 391